A limited case series have described that five out of eight pancreatic cancer patients with GPVs in ATM, ATR, or CHEK2 demonstrated a clinical benefit to oxaliplatin-based chemotherapy [119]; however, to our knowledge, there are no previous reports demonstrating efficacy to platinum agents in BC patients with ATM GPVs. The gene discussed is ATR; the disease is familial pancreatic carcinoma.